Conditions: Asthma
Keywords: Severe asthma, non-atopic, omalizumab
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 79
Healthy volunteers: no

Brief summary:
This study will assess the change in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe persistent asthma, uncontrolled despite optimal therapy.

Detailed description:

Arms:
arm 1: Participants received subcutaneous injections of omalizumab every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight. arm 2: Participants received subcutaneous injections of placebo to omalizumab every 2 weeks or every 4 weeks.

Interventions: intervention 1: omalizumab intervention 2: Placebo
Intervention descriptions: intervention 1: Omalizumab was supplied in 5mL vials with solution for subcutaneous injection. intervention 2: Placebo was supplied in vials with solution for subcutaneous injection.

Protocol document: